Eton Pharmaceuticals Plans Phase 2 Mecasermin Trial in Q1 2027
Eton Pharmaceuticals plans a Phase 2 mecasermin trial for pediatric epileptic spasms in Q1 2027.
Story updates
11:57:07 AM UTC
SquawkNews
Eton submitted a research IND for an investigator-sponsored Phase 2 mecasermin study in children with refractory epileptic spasms. Enrollment and dosing are targeted for Q1 2027; the study is expected to enroll up to 20 patients.Material DetailsContext by AI AnalystET-900 is at an early clinical-de…